公开(公告)号：EP3052103A1

公开(公告)日：2016-08-10

申请号：EP14780847.1

申请日：2014-10-03

申请人： AB Science ,  ACOBIOM

发明人： PIQUEMAL, David ,  MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/496 ,  A61K31/7068 ,  C12Q1/68 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  C12Q1/68 ,  C12Q1/686 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： The present invention relates to an in vitro method for determining the prognosis of pancreatic cancer in a patient. More particularly, this method comprises the following steps: a) measuring the expression level of at least one gene chosen in the group consisting in: ACOX-1, TNFRSF10B, LYN, HIF1A, UBE2H, PARP2, ABCC1, ABCC3, IGJ and RPS23 or homologous genes, in a blood sample of said patient, b) predicting the outcome of the pancreatic cancer in said patient. The invention also relates to a kit specifically designed to carry out such a method.

公开(公告)号：EP3368032A1

公开(公告)日：2018-09-05

申请号：EP16794960.1

申请日：2016-10-28

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre ,  MANSFIELD, Colin

IPC分类号： A61K31/352 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/519 ,  A61K31/661 ,  A61P25/16

CPC分类号： A61K31/496 ,  A61K31/352 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/519 ,  A61K31/661 ,  A61K45/06 ,  A61P25/16

摘要： Disclosed is a mast cell inhibitor, a pharmaceutical composition and a method for the treatment of patients afflicted with Parkinson's disease, wherein the patients are treated with a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a compound selected from imatinib, cromolyn sodium, midostaurin, BLU-285, bosutinib, ibrutinib, LAS189386, DP-2618, fostamatinib, dasatinib, sunitinib, axitinib, pazopanib, and toceranib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.

公开(公告)号：EP2117531B1

公开(公告)日：2016-11-02

申请号：EP08707865.5

申请日：2008-01-11

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/337 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/7068 ,  A61P35/00

CPC分类号： A61K31/426 ,  A61K31/337 ,  A61K31/421 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/7068 ,  A61K2300/00

公开(公告)号：EP1461032B1

公开(公告)日：2008-07-16

申请号：EP02801980.0

申请日：2002-09-20

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/506 ,  A61P17/14

CPC分类号： A61Q7/00 ,  A61K8/4953 ,  A61K31/00 ,  A61K31/015 ,  A61K31/095 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/505 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  A61K2800/782 ,  G01N33/5047 ,  G01N2333/5403 ,  G01N2333/705 ,  G01N2333/70596 ,  G01N2333/91215 ,  G01N2500/10 ,  A61K2300/00

摘要： The present invention relates to a method for promoting hair growth, preventing or minimizing hair loss comprising administering a tyrosine kinase inhibitor to a human in a need of such treatment, more particularly a non-toxic, selective and potent c-kit inhibitor. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

公开(公告)号：EP1653934B1

公开(公告)日：2008-05-14

申请号：EP04769332.0

申请日：2004-08-16

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/00 ,  A61P3/10

CPC分类号： A61K31/47 ,  A61K31/404 ,  A61K31/426 ,  A61K31/506

摘要： The present invention relates to a method for treating type II diabetes, comprising administering a compound capable of depleting mast cells to a human in need of such treatment. Such compounds can be chosen from non-toxic, selective and potent c-kit inhibitors.

公开(公告)号：EP1746990A1

公开(公告)日：2007-01-31

申请号：EP05741018.5

申请日：2005-04-19

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/404 ,  A61K31/421 ,  A61K31/425 ,  A61K31/506 ,  A61K31/517 ,  A61P37/08

CPC分类号： A61K31/421 ,  A61K31/404 ,  A61K31/425 ,  A61K31/426 ,  A61K31/506 ,  A61K31/517

摘要： The present invention relates to a method for treating patients exposed to chemical or biological weapons comprising administering a compound capable of depleting mast cells or a compound inhibiting mast cells degranulation, to a human in need of such treatment. Such compounds can be chosen from c-kit inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence of IL-3.

公开(公告)号：EP1434990A2

公开(公告)日：2004-07-07

申请号：EP02755509.3

申请日：2002-06-28

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： G01N33/50

CPC分类号： A61Q7/00 ,  A61K8/4953 ,  A61K31/00 ,  A61K31/015 ,  A61K31/095 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/498 ,  A61K31/50 ,  A61K31/505 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/66 ,  A61K45/06 ,  A61K2800/782 ,  G01N33/5047 ,  G01N2333/5403 ,  G01N2333/705 ,  G01N2333/70596 ,  G01N2333/91215 ,  G01N2500/10 ,  G01N2800/20 ,  A61K2300/00

摘要： The present invention relates to a screening method allowing the identification and selection of compounds capable of depleting mast cells, wherein said compounds do not show significant toxicity for other hematopeitic cells that are not mast cells or related cells or cell lines, such as SCF independent expanded human normal CD34+ cells.

公开(公告)号：EP4069230A1

公开(公告)日：2022-10-12

申请号：EP20816176.0

申请日：2020-12-02

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/496 ,  A61K45/06 ,  A61P11/06

公开(公告)号：EP3831384A1

公开(公告)日：2021-06-09

申请号：EP19306550.5

申请日：2019-12-02

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/496 ,  A61K45/06 ,  A61P11/06

摘要： The present invention relates to a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of asthma in a subject in need thereof, wherein the subject has an elevated level of eosinophils. In particular, the present invention relates to a 2-aminoarylthiazole derivative or a pharmaceutically acceptable salt or solvate thereof, in particular masitinib or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of asthma in a subject with an eosinophil blood count at baseline ranging from 150 cells/µL to 300 cells/µL.

公开(公告)号：EP1471907B1

公开(公告)日：2008-07-16

申请号：EP02765159.5

申请日：2002-06-28

申请人： AB Science

发明人： MOUSSY, Alain ,  KINET, Jean-Pierre

IPC分类号： A61K31/506 ,  A61P17/00 ,  A61P37/00 ,  A61P1/16

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/015 ,  A61K31/095 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/498 ,  A61K31/50 ,  A61K31/505 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/66 ,  G01N2333/70596 ,  G01N2800/20 ,  G01N2800/24 ,  G01N2800/245 ,  A61K2300/00

摘要： The present invention relates to a method for treating autoimmune diseases, more particularly selected from the group consisting of multiple sclerosis, ulcerative colitis, Crohn's disease, rheumatoid arthritis and polyarthritis, scleroderma, lupus erythematosus, dermatomyositis, pemphigus, polymyositis, vasculitis, as well as graft- versus host diseases, comprising administering a compound capable of depleting mast cells to a mammal in need of such treatment. Such compounds can be chosen from tyrosine kinase inhibitors and more particularly non-toxic, selective and potent c-kit inhibitors. Preferably, said inhibitor is unable to promote death of IL-3 dependent cells cultured in presence ofIL-3.